• 4/6/2006
  • Washington, DC
  • press release
  • tradingmarkets.com

IMPAX Laboratories Inc. said that U.S. Food and Drug Administration has approved the Abbreviated New Drug Application for a generic version of Salagen 5 and 7.5 mg Tablets.

MGI Pharma Inc. markets Salagen Tablets for the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and for the treatment of symptoms of dry mouth in patients with Sjogren’s Syndrome.